Trade Report: The CME Group Inc. (CME) Receives “Buy” Rating from Jefferies Group

The CME Group Inc. (CME) Receives “Buy” Rating from Jefferies Group

Jefferies Group reissued their buy rating on shares of CME Group Inc. (NASDAQ:CME) in a research report report published on Thursday morning. The brokerage currently has a $118.00 target price on the stock.

A number of other equities research analysts also recently weighed in on CME. Deutsche Bank AG raised their price target on shares of CME Group from $110.00 to $111.00 and gave the company a buy rating in a research note on Friday, July 29th. JPMorgan Chase & Co. raised their price target on shares of CME Group from $99.00 to $106.00 and gave the company an overweight rating in a research note on Friday, July 29th. Zacks Investment Research upgraded shares of CME Group from a sell rating to a hold rating in a research note on Thursday, June 30th. Barclays PLC reduced their price target on shares of CME Group from $100.00 to $99.00 and set an equal weight rating on the stock in a research note on Friday, July 29th. Finally, Keefe, Bruyette & Woods raised their price target on shares of CME Group from $99.00 to $103.00 and gave the company a market perform rating in a research note on Friday, July 29th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the stock. The company has an average rating of Hold and an average price target of $103.27.

Shares of CME Group (NASDAQ:CME) traded up 0.96% during midday trading on Thursday, reaching $104.92. 330,980 shares of the company’s stock traded hands. CME Group has a 52-week low of $81.87 and a 52-week high of $110.35. The stock has a 50-day moving average price of $106.49 and a 200-day moving average price of $99.63. The stock has a market cap of $35.55 billion, a P/E ratio of 26.49 and a beta of 0.83.

CME Group (NASDAQ:CME) last announced its quarterly earnings data on Thursday, July 28th. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.03. The firm had revenue of $906 million for the quarter, compared to the consensus estimate of $897.84 million. CME Group had a net margin of 38.22% and a return on equity of 6.83%. The business’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.95 earnings per share. Analysts forecast that CME Group will post $4.43 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 26th. Stockholders of record on Friday, September 9th were paid a $0.60 dividend. The ex-dividend date was Wednesday, September 7th. This represents a $2.40 annualized dividend and a dividend yield of 2.31%. CME Group’s dividend payout ratio is currently 60.61%.

In other CME Group news, Director Martin J. Gepsman sold 300 shares of the business’s stock in a transaction on Friday, September 2nd. The shares were sold at an average price of $109.00, for a total transaction of $32,700.00. Following the completion of the sale, the director now owns 42,802 shares in the company, valued at approximately $4,665,418. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Phupinder Gill sold 30,002 shares of the business’s stock in a transaction on Monday, September 19th. The shares were sold at an average price of $110.00, for a total transaction of $3,300,220.00. Following the sale, the chief executive officer now owns 116,222 shares of the company’s stock, valued at approximately $12,784,420. The disclosure for this sale can be found here. 0.61% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC raised its stake in shares of CME Group by 447.6% in the second quarter. Tower Research Capital LLC TRC now owns 1,621 shares of the company’s stock worth $157,000 after buying an additional 1,325 shares during the period. Parametrica Management Ltd purchased a new position in CME Group during the second quarter worth about $212,000. Independent Portfolio Consultants Inc. purchased a new position in CME Group during the third quarter worth about $227,000. Private Advisor Group LLC purchased a new position in CME Group during the second quarter worth about $214,000. Finally, Ranger International Management LP purchased a new position in CME Group during the second quarter worth about $219,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

About CME Group

Related posts

Leave a Comment